A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
22actual
Sites
1
Country
Taiwan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-04 | actual | When the study began enrolling |
| Primary completion | 2026-04-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-14 | actual | The whole study's end, after follow-up |
| First posted | 2024-11-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Carcinoma, Non-Small-Cell Lung
Intervention
- Drug: Lorlatinib — also filed as PF-6463992
Primary outcomes
what the primary-completion date above is the date OFreal-world progression-free survival
measured 74 months from 1st April, 2018
The overall survival (OS)
measured 74 months from 1st April, 2018
The real world time to next treatment (rwTTNT)
measured 74 months from 1st April, 2018
The real world intracranial progression free survival (rwICPFS)
measured 74 months from 1st April, 2018
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed